Skip to Main Content

Paper Details

Reassessing the Benefits and Harms of Risk-Reducing Medication Considering the Persistent Risk of Breast Cancer Mortality in Estrogen Receptor-Positive Breast Cancer.
J Clin Oncol
2
2023
Author NameAffiliation
Kathryn P LowryUniversity of Washington
Stephen M SchwartzGeorgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center
Karen J WernliKaiser Permanente Washington Health Research Institute
Karen J WernliKaiser Permanente Washington Health Research Institute
Claudine IsaacsGeorgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center
  • 1 - 5

Datasets

Release 1.2